Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study
Abstract Aim To evaluate the effectiveness of empagliflozin in clinical practice in East Asia in the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) East Asia study. Materials and methods Data were obtained from the Medical Data Vision database (Japan), National Health Insurance Service...
Main Authors: | Yutaka Seino, Dae Jung Kim, Daisuke Yabe, Elise Chia‐Hui Tan, Wook‐Jin Chung, Kyoung Hwa Ha, Masaomi Nangaku, Koichi Node, Riho Klement, Atsutaka Yasui, Wei‐Yu Lei, Sunwoo Lee, Moe H. Kyaw, Anouk Deruaz‐Luyet, Kimberly G. Brodovicz, Wayne H.‐H. Sheu, the EMPRISE East Asia study group |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-01-01
|
Series: | Endocrinology, Diabetes & Metabolism |
Subjects: | |
Online Access: | https://doi.org/10.1002/edm2.183 |
Similar Items
-
Empagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in routine care in East Asia: Results from the EMPRISE study
by: Dae Jung Kim, et al.
Published: (2023-03-01) -
Healthcare resource utilization in patients treated with empagliflozin in East Asia
by: Wayne H‐H Sheu, et al.
Published: (2022-05-01) -
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia
by: Dorte Vistisen, et al.
Published: (2023-08-01) -
The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care
by: Elisabetta Patorno, et al.
Published: (2020-01-01) -
Options for empagliflozin in combination therapy in type 2 diabetes mellitus
by: Hershon KS
Published: (2016-05-01)